



UNDERSTANDING YOUR TREATMENT WITH PAVBLU™



FROM AMGEN, A WORLDWIDE LEADER IN BIOLOGICS

PAVBLU™ is an FDA-approved prescription medicine for treatment of patients with:

- ▶ Neovascular (Wet) Age-Related Macular Degeneration, known as “Wet AMD”
- ▶ Macular Edema Following Retinal Vein Occlusion (RVO)
- ▶ Diabetic Macular Edema (DME)
- ▶ Diabetic Retinopathy (DR)

FDA = Food and Drug Administration.

PAVBLU™ is not indicated for Retinopathy of Prematurity, for which Regeneron has marketing exclusivity.^{1,2}

PAVBLU™ (aflibercept-ayyh) Injection is a prescription medicine administered by injection into the eye. You should not use PAVBLU™ if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in PAVBLU™.

Please see **full Important Safety Information** on page 9.

UNDERSTANDING YOUR DIAGNOSIS



IF YOU'VE BEEN DIAGNOSED WITH

WET AMD

Neovascular
(Wet) Age-
Related-Macular
Degeneration
(AMD)

DME, DR

Diabetic Macular
Edema (DME)
or Diabetic
Retinopathy (DR)

RVO

Macular Edema
Following Retinal
Vein Occlusion
(RVO)

YOU MAY BE EXPERIENCING SOME OF THE FOLLOWING SYMPTOMS:³⁻⁵




- ▶ *Straight lines begin to look wavy or crooked*
- ▶ *Blurry area near the center of your vision*
- ▶ *Blank spots or dark spots (like a smudge on glass) may appear in your vision*
- ▶ *Trouble seeing in low light*
- ▶ *Sudden blurring or loss of vision (over days to weeks)*

Important Safety Information (continued)

- Injections into the eye with PAVBLU™ can result in an infection in the eye, retinal detachment (separation of retina from back of the eye) and, more rarely, serious inflammation of blood vessels in the retina that may include blockage. Call your doctor right away if you experience eye pain or redness, light sensitivity, or a change in vision after an injection.

IS THERE A TREATMENT FOR THESE CONDITIONS?

PAVBLU™ is an anti-VEGF treatment that can help with these conditions. VEGF (vascular endothelial growth factor) is a protein made by cells that contributes to the growth of blood vessels. When this protein is produced at high levels, it can lead to an overgrowth of blood vessels and cause them to leak fluid. PAVBLU™ helps to block that protein.⁶



● VEGF

When too much VEGF is produced in your eye, it causes new blood vessels to grow. These growing vessels are leaky causing fluid to build up in your eye, which worsens your vision.



PAVBLU™


Helps block VEGF and slows the growth of blood vessels in the eye that can leak fluid

Important Safety Information (*continued*)

- In some patients, injections with PAVBLU™ may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.

Please see **full Important Safety Information** on page 9.

PAVBLU™—A TREATMENT FOR RETINAL CONDITIONS



PAVBLU™ is a biosimilar of the biologic medicine called EYLEA®.¹

Both PAVBLU™ and EYLEA® work with your body to help stop or slow the progression of certain retinal conditions. PAVBLU™ is proven to provide a similar treatment benefit to EYLEA®.^{1,2,7}

PAVBLU™ may help stop or slow the progression of symptoms of your retinal disease, and could help you maintain your current level of vision.¹

PAVBLU™ is an FDA-approved medication given by your doctor in the same way and on the same schedule as EYLEA® for a **highly similar treatment experience^{1,2}**

Important Safety Information (*continued*)

- There is a potential but rare risk of serious and sometimes fatal side effects, related to blood clots, leading to heart attack or stroke in patients receiving PAVBLU™.

Please see **full Important Safety Information** on page 9.

WHAT TO KNOW WHEN STARTING PAVBLU™

Here's some helpful information to know **when your doctor starts you on PAVBLU™**



HOW IT IS GIVEN:

PAVBLU™ is administered by a retina specialist as an injection to the eye.¹ Your doctor will examine, wash, and numb your eye before injection.



HOW OFTEN:

PAVBLU™ is typically given monthly when you are beginning treatment, but your retina specialist will determine the best dosing schedule for you, dependent upon your retina condition.¹



SAFE & EFFECTIVE:

PAVBLU™ is an FDA-approved biosimilar medication for EYLEA®.¹ Biosimilars go through a rigorous FDA-approval process to ensure they are safe and effective.⁸

Important Safety Information (*continued*)

- The most common side effects reported in patients receiving PAVBLU™ were increased redness in the eye, eye pain, cataract, vitreous detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.

SUPPORT THROUGHOUT YOUR TREATMENT JOURNEY



AMGEN® Support⁺

With financial support resources and other helpful patient support services, we are here to help you along the way.

***Once you have been prescribed PAVBLU™,
Amgen SupportPlus is here to help***



***Visit AmgenSupportPlus.com or call Amgen
SupportPlus at (866) 264-2778
Monday–Friday 9:00 am–8:00 pm ET***

Important Safety Information (*continued*)

- You may experience temporary visual changes after a PAVBLU™ injection and associated eye exams; do not drive or use machinery until your vision recovers sufficiently.

Please see **full Important Safety Information** on page 9.

FINANCIAL INFORMATION AND RESOURCES

FINANCIAL SUPPORT

Every patient has unique needs. We're here to provide financial support information and resources, regardless of your current financial situation or the type of insurance you have.

GOVERNMENT INSURANCE, UNINSURED, OR UNDERINSURED

If you have government insurance, like Medicare, or are uninsured or underinsured, Amgen® SupportPlus can provide information about resources that may be able to lower your out-of-pocket costs.*

*Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides information as a courtesy only.

AMGEN® SupportPlus CO-PAY PROGRAM



If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible for the Amgen SupportPlus Co-Pay Program.*



- Eligible patients may pay as little as \$0 out-of-pocket for each dose and receive up to \$1,000 per calendar year for in-office administration out-of-pocket costs*
- No income eligibility requirement

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions. Massachusetts and Rhode Island residents not eligible for in-office administration support.

Enroll online at
AmgenSupportPlus.com/copay



IMPORTANT SAFETY INFORMATION

- PAVBLU™ (aflibercept-ayyh) Injection is a prescription medicine administered by injection into the eye. You should not use PAVBLU™ if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in PAVBLU™.
- Injections into the eye with PAVBLU™ can result in an infection in the eye, retinal detachment (separation of retina from back of the eye) and, more rarely, serious inflammation of blood vessels in the retina that may include blockage. Call your doctor right away if you experience eye pain or redness, light sensitivity, or a change in vision after an injection.
- In some patients, injections with PAVBLU™ may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
- There is a potential but rare risk of serious and sometimes fatal side effects, related to blood clots, leading to heart attack or stroke in patients receiving PAVBLU™.
- The most common side effects reported in patients receiving

PAVBLU™ were increased redness in the eye, eye pain, cataract, vitreous detachment, vitreous floaters, moving spots in the field of vision, and increased pressure in the eye.

- You may experience temporary visual changes after a PAVBLU™ injection and associated eye exams; do not drive or use machinery until your vision recovers sufficiently.
- For additional safety information, please talk to your doctor and see the **full Prescribing Information** for PAVBLU™.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

PAVBLU™ (aflibercept-ayyh) is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for PAVBLU™.

PAVBLU™ IS A BIOSIMILAR OF THE BIOLOGIC MEDICINE CALLED EYLEA®¹

PAVBLU™ CAN BE USED IN PLACE OF EYLEA®
WITHOUT COMPROMISING TREATMENT BENEFIT⁶

PAVBLU™ is an FDA-approved prescription medication used to treat the following eye conditions:¹

- ▶ Neovascular (Wet) Age-Related Macular Degeneration, known as “Wet AMD”
- ▶ Macular edema following retinal vein occlusion (RVO)
- ▶ Diabetic macular edema (DME)
- ▶ Diabetic retinopathy (DR)

PAVBLU™ is not indicated for Retinopathy of Prematurity, for which Regeneron has marketing exclusivity.^{1,2}

AMGEN® Support⁺

We're right here when you need us



**Call Amgen® SupportPlus at (866) 264-2778
Monday to Friday 9:00 am to 8:00 pm ET**

Or visit AmgenSupportPlus.com to learn how Amgen can help



Learn more at **PAVBLU.com**



References: **1.** PAVBLU™ (aflibercept-ayyh) Prescribing Information, Amgen. 2024. **2.** Eylea® [aflibercept] Prescribing Information, Regeneron Pharmaceuticals Inc. 2024. **3.** Mehta S. Age-related macular degeneration (AMD or ARMD). Merck Manual. April 2024. www.merckmanuals.com/professional/eye-disorders/retinal-disorders/age-related-macular-degeneration-amd-or-armd. Accessed July 24, 2024. **4.** Stahl A. The diagnosis and treatment of age-related macular degeneration. *Dtsch Arztebl Int.* 2020;117:513–520. **5.** Cleveland Clinic. Retinal vein occlusion (RVO). my.clevelandclinic.org/health/diseases/14206-retinal-vein-occlusion-rvo. Accessed July 24, 2024. **6.** Stahl A. The diagnosis and treatment of age-related macular degeneration. *Dtsch Arztebl Int.* 2020;117:513–520. **7.** Data on file, Amgen. [CSR 20170542]; 2024. **8.** US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. www.fda.gov/media/82647/download. Accessed June 5, 2024.

EYLEA® is a registered trademark of Regeneron Pharmaceuticals, Inc.

PAVBLU™ is a trademark of Amgen Inc.

Please see **full Important Safety Information** on page 9.